相关实验视频
Updated: Jul 15, 2025

05:51
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
13.2K
动脉样硬化中的炎症细胞 - - 从病理生理学到治疗
Panagiotis Theofilis1, Evangelos Oikonomou2, Christos Chasikidis3
11st Department of Cardiology, "Hippokration" General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Pharmaceuticals (Basel, Switzerland)
|September 28, 2023
概括
炎症酶,关键的免疫激活剂,通过促进动脉斑块驱动动动脉硬化. 准这些炎症酶可以为心血管疾病提供有前途的新疗法.
科学领域:
- 心血管研究研究心血管研究
- 免疫学 免疫学 免疫学
- 分子医学是分子医学.
背景情况:
- 动脉样硬化是一种慢性炎症性疾病,由动脉斑块积累驱动.
- 炎症酶对天生的免疫力至关重要,越来越多地被认为是动脉样硬化的核心参与者.
- 了解炎细胞的参与对于应对这一全球性健康挑战至关重要.
研究的目的:
- 在动脉样硬化中提供炎症酶激活的全面审查.
- 阐明将炎症体与斑块发育和不稳定性联系起来的机制.
- 检查针对动脉样硬化的炎症体的新兴治疗策略.
主要方法:
- 文献综述和分析有关炎症和动脉样硬化的当前研究.
- 探索涉及模式识别受体和细胞因子的分子通路.
- 综合关于炎症酶对内皮功能障碍和血管炎症的贡献的证据.
主要成果:
- 炎症酶激活会通过延续炎症级联加剧动脉样硬化.
- 传统的心血管风险因素与炎症体相互作用,促进斑块的形成.
- 炎症体对内皮功能障碍,泡细胞形成和血管炎症有显著的贡献.
结论:
- 针对炎症酶的向疗法在动脉样硬化管理方面具有显著的潜力.
- 了解炎症途径为个性化心血管治疗提供了前景.
- 调节炎症酶活性可以减轻动脉样硬化负担并改善患者的治疗结果.
相关概念视频
Inflammation
53.8K
Overview
53.8K
Atherosclerosis I: Introduction
9
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
9
Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
Coronary Artery Disease II: Pathophysiology
12
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
12
Coronary Artery Disease I: Introduction
20
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
20
Peripheral Artery Disease I: Introduction
9
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs but also impacts other areas, such as the arms, thereby impairing overall circulation and organ function.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty deposits inside the arterial...
9

